Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Basal Ganglia Diseases
Description
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. MeSH
Hierarchy View
Subtype Terms (12)
Basal Ganglia Cerebrovascular Disease
Hepatolenticular Degeneration
18 drugs (10 approved, 8 experimental)
Huntington Disease
90 drugs (43 approved, 47 experimental)
Meige Syndrome
2 drugs (1 approved, 1 experimental)
Multiple System Atrophy
60 drugs (36 approved, 24 experimental)
Pantothenate Kinase-Associated Neurodegeneration
2 drugs (1 approved, 1 experimental)
Parkinsonian Disorders
44 drugs (17 approved, 27 experimental)
Supranuclear Palsy, Progressive
50 drugs (24 approved, 26 experimental)
Tourette Syndrome
48 drugs (31 approved, 17 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (5)
Phase 1 Indicated Drugs (1)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 1 Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
